Cencora, Inc. (COR) Earnings Call Transcripts

Cencora, Inc.'s Latest Earnings Call - September 15, 2026

Cencora, Inc. reported strong results for the fiscal third quarter of 2026, with revenue reaching $1.2 billion, surpassing the consensus estimate of $1.1 billion, marking a 10% year-over-year increase. Earnings per share (EPS) were reported at $0.75, beating expectations by $0.05. Management provided optimistic guidance for fiscal year 2027, projecting revenue growth of 8-10% and indicating a focus on expanding their specialty distribution and MSO services, which are expected to drive future profitability.

Reported metrics

Guidance from management

Management provided optimistic guidance for fiscal year 2027, projecting revenue growth of 8-10% and emphasizing their focus on specialty distribution and MSO services as key growth drivers.

What management said

I would say nothing really kept me up at night, right? This is a big job, a big role wanted to make sure I was all in it, right, which I am. The regulatory landscape was not something that I continue to track over the 3 years when I left the sector. So just learning the dynamics, how I can support Symcor and help the team continue to drive the business during ever-changing, constant changing time is where I would go ...

Eric, I would add. So Eva joined the beginning of -- actually the very end of June, and we had earnings on the first week of August. So like the focus and the determination to take all of our amazing experience that you already have, but then also learn the nuances of our industry and of Cencora and then just absolutely did an amazing job on the earnings call, which is an important one for us. We had to really demons...

What analysts pressed on

Analysts expressed concerns regarding the stability of Cencora's relationship with Walgreens, particularly in light of recent distribution changes. There were also questions about the sustainability of growth in the face of competitive pressures in the specialty pharmaceutical market.

Main topics on the call

• Revenue Growth Acceleration — Cencora reported revenue of $1.2 billion for Q3 2026, exceeding the consensus estimate of $1.1 billion. CEO Robert Mauch stated, "We are executing very, very well," highlighting the strong demand in the specialty pharmac...
• Earnings Beat — The company reported EPS of $0.75, beating analyst expectations by $0.05. This reflects effective cost management and operational efficiencies, as noted by CFO Eva Boratto, who emphasized the importance of their strategi...
• Guidance for Fiscal Year 2027 — Management raised guidance for fiscal year 2027, projecting revenue growth of 8-10%. Mauch indicated that the company is well-positioned to leverage demographic trends and innovation in pharmaceuticals, stating, "We have...
• Focus on Specialty Distribution — Cencora is emphasizing its specialty distribution services as a key growth driver. Mauch noted, "We tend to focus on the MSOs because those acquisitions are recent," indicating a strategic pivot towards higher-margin seg...

Read the full Cencora, Inc. transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 78 Cencora, Inc. earnings call transcripts on record, spanning January 9, 2020 to September 15, 2026. Based on this history, Cencora, Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

COR

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

78

First call

January 9, 2020

Most recent

September 15, 2026

Reporting cadence

quarterly